Stryker Corporation $SYK Shares Sold by Syon Capital LLC

Syon Capital LLC decreased its holdings in shares of Stryker Corporation (NYSE:SYK) by 25.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,771 shares of the medical technology company’s stock after selling 1,978 shares during the quarter. Syon Capital LLC’s holdings in Stryker were worth $1,817,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in SYK. Sankala Group LLC acquired a new stake in Stryker during the fourth quarter worth approximately $26,000. Godfrey Financial Associates Inc. acquired a new position in shares of Stryker in the 4th quarter valued at $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker in the 3rd quarter valued at $27,000. Atlas Capital Advisors Inc. purchased a new position in shares of Stryker in the 4th quarter valued at $27,000. Finally, Gables Capital Management Inc. acquired a new stake in Stryker during the 2nd quarter worth $25,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Trading Down 1.6%

NYSE:SYK opened at $302.92 on Friday. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.37. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The stock’s 50 day simple moving average is $328.84 and its 200-day simple moving average is $329.73. The firm has a market cap of $116.19 billion, a P/E ratio of 31.39, a PEG ratio of 1.93 and a beta of 0.76.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same period last year, the company earned $3.13 earnings per share. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts anticipate that Stryker Corporation will post 15.03 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is 36.48%.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of research reports. JPMorgan Chase & Co. reduced their price target on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Royal Bank Of Canada cut their target price on Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Truist Financial boosted their target price on Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a report on Friday, July 31st. Citizens Jmp decreased their target price on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday, August 3rd. Finally, Piper Sandler dropped their price target on Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Insider Activity

In related news, Director Ronda E. Stryker sold 50,000 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the transaction, the director directly owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Debra King sold 826 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 351,267 shares of company stock valued at $118,197,701 over the last quarter. Corporate insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.